Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

125.95 +4.47 (+3.68%)
Streaming Delayed Price Updated: 12:34 PM EDT, Jun 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
74 75 Next >
News headline image
Uncover the latest developments among S&P500 stocks in today's session. ↗
Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview. 
Via Chartmill
News headline image
Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Therapy Targeting Brain Cancer at 2025 ASCO and EHA
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Is the Market Bullish or Bearish on Gilead Sciences? ↗
 
Via Benzinga
News headline image
Thermo Fisher, Biogen, Gilead Sciences, Moderna, and QuidelOrtho Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after the major indices popped (Nasdaq +3.4%, S&P 500 +2.5%) in response to the positive outcome of U.S.-China trade negotiations, as both sides... 
Via StockStory
Topics Government Stocks World Trade
News headline image
Top S&P500 movers in Monday's pre-market session ↗
Stay updated with the S&P500 stocks that are on the move in today's pre-market session. 
Via Chartmill
News headline image
S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price Reform ↗
It's still unclear how President Donald Trump plans to tie drug prices in the U.S. to international prices. 
Via Investor's Business Daily
Topics Government Stocks
News headline image
Wall Street Rips Higher As Tariff Truce Halts US–China Economic Escalation ↗
US-China agree to slash tariffs by over 100%, easing fears of economic slowdown and inflation. Markets cheer with futures rising and yields up. 
Via Benzinga
Topics Economy World Trade
News headline image
GILD Q1 Earnings Call: HIV Growth and Pipeline Momentum Offset Revenue Miss
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) missed Wall Street’s revenue expectations in Q1 CY2025, with sales flat year on year at $6.67 billion. The company’s full-year revenue guidance... 
Via StockStory
News headline image
2 High-Yield Dividend Stocks to Buy in May and Hold Forever ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Market Monitor May 9 (Boeing, MicroStrategy UP - Match Group DOWN) ↗
U.S. stocks rally amid steady Fed rates, strong Disney and AMD earnings, but Alphabet falls on Apple concerns. 
Via Chartmill
Topics Economy
News headline image
3 Value Stocks with Mounting Challenges
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are... 
Via StockStory
News headline image
Marjorie Taylor Greene Goes Stock Shopping Again: Here Are 50+ Stocks The Congresswoman Bought ↗
Marjorie Taylor Greene disclosed buying more than 50 stocks in early May. A look at the list and why the congresswoman's past trades have drawn red flags. 
Via Benzinga
News headline image
Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead’s Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Market Monitor May 7 ( Hims & Hers Health, Upwork UP - Palantir, Monderna DOWN) ↗
Markets slide on vaccine regulation fears, trade uncertainty, and cautious earnings despite strong tech and consumer stock moves. 
Via Chartmill
News headline image
GILEAD SCIENCES INC (NASDAQ:GILD) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗
When you look at GILEAD SCIENCES INC (NASDAQ:GILD), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
News headline image
1 Profitable Stock on Our Watchlist and 2 to Turn Down
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
Via StockStory
News headline image
3 Biotech Giants Gaining From U.S. Sales and Policy Shifts
The significant domestic revenue base of select US biotech companies offers stability potential for investors navigating global trade complexities. 
Via MarketBeat
Topics Economy World Trade
News headline image
Gilead Sciences Inc (NASDAQ:[GILD](https://www.chartmill.com/stock/quote/GILD)): A Dividend Stock Worth Considering ↗
Gilead Sciences Inc (NASDAQ:[GILD](https://www.chartmill.com/stock/quote/GILD)): A Dividend Stock Worth Considering 
Via Chartmill
News headline image
These 3 Funds Offer Sky-High Yields of 15% or More and Trade at a Discount ↗
Via The Motley Fool
News headline image
Moderna (MRNA) Reports Earnings Tomorrow: What To Expect
Biotechnology company Moderna (NASDAQ:MRNA) will be announcing earnings results tomorrow before market hours. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence World Trade
News headline image
Amgen (AMGN) Reports Earnings Tomorrow: What To Expect
Biotech company Amgen (NASDAQ:AMGN) will be reporting earnings tomorrow afternoon. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence Economy World Trade
News headline image
Biogen Earnings: What To Look For From BIIB
Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow before the bell. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence World Trade
News headline image
What To Expect From BioMarin Pharmaceutical’s (BMRN) Q1 Earnings
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting earnings tomorrow after the bell. Here’s what to look for. 
Via StockStory
Topics Artificial Intelligence World Trade
News headline image
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis
From Gilead Sciences, Inc.
Via Business Wire
News headline image
United Therapeutics (UTHR) To Report Earnings Tomorrow: Here Is What To Expect
Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting earnings tomorrow morning. Here’s what to look for. 
Via StockStory
Topics Government World Trade
News headline image
Large Cap Biopharmaceutical Update: Mixed Performance As Tariffs Loom ↗
Biopharma stocks rally along with many of our SMID cap trades. The market situation with pharmaceuticals is even more complicated because we started off with legislation (the IRA) trying to curb rising... 
Via Talk Markets
Topics ETFs Stocks / Equities
News headline image
These S&P500 stocks are moving in today's session ↗
Curious about the top performers within the S&P500 index one hour before the close of the markets on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive... 
Via Chartmill
News headline image
Exploring the top movers within the S&P500 index during today's session. ↗
Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview. 
Via Chartmill
< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
74 75 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.